{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:19:19Z","timestamp":1783487959957,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK065988"],"award-info":[{"award-number":["P30 DK065988"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002489"],"award-info":[{"award-number":["UL1TR002489"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007930","name":"Institute of Clinical and Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["DESPOT20B0"],"award-info":[{"award-number":["DESPOT20B0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jcf.2023.10.002","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T16:39:17Z","timestamp":1697128757000},"page":"1024-1026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8464-6946","authenticated-orcid":false,"given":"Katherine A.","family":"Despotes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9031-1166","authenticated-orcid":false,"given":"Agathe S.","family":"Ceppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcf.2023.10.002_bib0001","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.jcf.2016.09.010","article-title":"Coronary artery disease in cystic fibrosis: an emerging concern?","volume":"15","author":"Skolnik","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.002_bib0002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcf.2021.04.016","article-title":"Cardiovascular complications in cystic fibrosis: a review of the literature","volume":"21","author":"Poore","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.10.002_bib0003","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1258\/jrsm.2010.s11010","article-title":"Ischaemic heart disease\u2013a new issue in cystic fibrosis?","volume":"103 Suppl 1","author":"Perrin","year":"2010","journal-title":"J R Soc Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.002_bib0004","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.10.002_bib0005","unstructured":"Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry: 2021 annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2021 [accessed 2022 Nov 23]. Available from: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"issue":"1","key":"10.1016\/j.jcf.2023.10.002_bib0006","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jcf.2021.11.013","article-title":"Acute ST-elevation myocardial infarction in two young women with cystic fibrosis and cystic fibrosis-related diabetes","volume":"21","author":"Thambuluru","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.002_bib0007","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1183\/09031936.00212511","article-title":"Increased arterial stiffness in children with cystic fibrosis: Table 1","volume":"39","author":"Buehler","year":"2012","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.002_bib0008","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00044009","article-title":"Increased augmentation index in patients with cystic fibrosis","volume":"34","author":"Hull","year":"2009","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.002_bib0009","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/ajcn\/75.6.1005","article-title":"Abnormal lipid concentrations in cystic fibrosis","volume":"75","author":"Figueroa","year":"2002","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.jcf.2023.10.002_bib0010","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1440-1843.2010.01771.x","article-title":"Metabolic abnormalities in adults with cystic fibrosis","volume":"15","author":"Georgiopoulou","year":"2010","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.002_bib0011","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jcf.2017.02.010","article-title":"Dietary intake and lipid profile in children and adolescents with cystic fibrosis","volume":"16","author":"Woestenenk","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.002_bib0012","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2012.08.012","article-title":"Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients","volume":"12","author":"Ishimo","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.002_bib0013","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2009.09.002","article-title":"Prevalence of dyslipidemia in adults with cystic fibrosis","volume":"9","author":"Rhodes","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.002_bib0014","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2019.04.001","article-title":"Cystic fibrosis dyslipidaemia: a cross-sectional study","volume":"18","author":"Nowak","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.002_bib0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.jcf.2023.10.002_bib0016","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2023.10.002_bib0017","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jcf.2023.10.002_bib0018","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","article-title":"Onset of systemic arterial hypertension after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis: a case series","volume":"21","author":"Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.002_bib0019","first-page":"285","article-title":"The relationship between lipid profile and severity of liver damage in cirrhotic patients","volume":"10","author":"Ghadir","year":"2010","journal-title":"Hepat Mon"},{"issue":"2","key":"10.1016\/j.jcf.2023.10.002_bib0020","article-title":"The pattern of dyslipidemia in chronic liver disease patients","volume":"13","author":"Farooque","year":"2021","journal-title":"Cureus"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:14:33Z","timestamp":1778620473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323009232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1569199323009232"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}